Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics reported in an 8-K filing with the US Securities and Exchange Commission today that it has entered into a credit agreement for a principal amount of $300 million.

The revolving credit facility includes $10 million sublimits for swingline loans and letters of credit. Myriad borrowed $205 million in revolving loans from the credit facility, which matures on December 23, 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.